Despite the vast differences in the timescales with which these leukocytes do their jobs, their recruitment and migration share many common themes. Yet, the fate of these different leukocyte classes varies considerably ( Figure) Beyond the classification of different leukocyte lineages, the last decade has witnessed an explosion in understanding the heterogeneity of leukocytes within a given group. 3 4 Virtually every leukocyte family includes various sub-types that subserve distinct functions and respond to and elaborate different, but often overlapping, patterns of mediators.
While the traditional view of leukocyte participation in inflammation portrays them as phlogistic proagonists, some leukocyte sub-types appear to quell or moderate inflammation. Examples of such leukocytes that can limit inflammation or promote repair include Th2 lymphocytes, regulatory T cells (Treg) M2 macrophages, and Ly6c lo monocytes. While some of the muting of inflammation mediated by certain leukocyte sub-types derives from the production of anti-inflammatory mediators such as IL-10 or transforming growth factor beta, recognition has increased that specific pathways of inflammation resolution,
7/8/15
Peter Libby, MD distinct from anti-inflammatory mediators, usually involving lipids, can help limit inflammatory responses. 5, 6 The translational challenge of inflammation in cardiovascular diseases On the more positive side of the balance sheet, the statin class of hydroxymethylglutaryl co-enzyme A inhibitors resoundingly reduces cardiovascular event rates, but the extent to which they do so by anti-inflammatory functions distinct from lowering of low-density lipoprotein cholesterol remains controversial. A small study showed an impressive reduction in cardiovascular events with treatment with colchicine, an agent that interferes with leukocyte functions. 7 This concept requires rigorous evaluation in a larger double-blind clinical trial. Methotrexate in low doses on a weekly dosing regimen has revolutionized the treatment of rheumatoid arthritis. A large clinical trial currently underway will evaluate its ability to reduce recurrent cardiovascular events in individuals at high risk. 8 Another trial targets p38 MAP kinase, a key participant in the control of inflammation, in secondary prevention of atherosclerotic events. 9 7/8/15
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Anti-cytokine treatment has also proven highly beneficial in some inflammatory diseases such as rheumatoid arthritis. Yet, the anti-tumor necrosis factor antibodies associated with a signal for worsened outcome when studied in large clinical trials for heart failure. A large-scale clinical trial currently underway tests whether a monoclonal antibody that targets interleukin-1-beta might improve outcomes in survivors of myocardial infarction with persistent inflammation (despite contemporary standard of care treatment), as gauged by increased levels of the inflammatory biomarker C-reactive protein. 10 In sum, while inflammatory pathways such as those discussed in this series of articles remain enticing targets for therapeutic intervention, the promise remains unfulfilled. Given the redundancy of inflammatory pathways, targeting any one mediator may not suffice to limit cardiovascular inflammation in a meaningful way. On the other hand, intervening in pathways that participate in host defense runs the risk of impairing tumor surveillance or the ability of the host to combat infection. Thus, application of the growing body of detailed mechanistic insight we are acquiring regarding pathways of cardiovascular inflammation, the therapeutic application will require finding the "sweet spot," where we selectively target the 
Status of Anti-Infammatory Agents in Atherothrombotic Disease
Anti-inflammatory strategies less likely to improve cardiovascular outcomes: Corticosteroids Non-steroidal anti-inflammatory drugs Anti-TNF agents
Anti-inflammatory strategies that might improve cardiovascular outcomes:
Colchicine -LoDoCo trial 7 , PROBE design, n=532
Anti-inflammatory strategies under evaluation in cardiovascular outcome trials:
Methotrexate (low dose weekly) -CIRT 8 , RCT, n=7,000 (enrolling) Anti-Interleukin-1 beta (canakinumab) -CANTOS 10 Monocytes recruited into tissues mature into macrophages. These cells exert phagocytic activity, and also elaborate a myriad of mediators of inflammation. The macrophage can replicate within tissues or die, including by apoptosis.
Mononuclear phagocytes may also emigrate into the lymph or blood. These processes generally play out over days or even years.
